Here is today's summary of economic development news, a free service of the Economic Development Partnership of Alabama, representing Alabama's private sector investment in economic development. If you enjoy NewsFlash, thank an
EDPA Partner.

Javelin Strategy & Research has ranked BBVA Compass a leader in ease of use and customer service on their mobile app.

Javelin Strategy & Research's Mobile Banking Scorecard looks at more than 200 features of the mobile banking apps from the nation's top 28 financial institutions to understand how they are managing customers' changing expectations for mobile banking experiences. It spotlights trends, best practices, and features that make a bank a leader in six categories: money movement, ease of use, security empowerment, financial fitness, customer service, and account opening.

Huntsville residents are one step closer to realizing some of the fastest mobile network speeds in the country, thanks to City Council's decision to approve a wireless rights of way use agreement with Uniti Fiber. The agreement permits the company, a leading provider of infrastructure solutions - including cell site backhaul and small cell for wireless operators- to construct small cells in the public right of way.

Small cells are the infrastructure that make 5G deployment possible. Hailed as the next evolution of cellular networks, 5G provides mobile users with virtually zero lag time and higher speeds. The network further supports growth of emerging technologies such as augmented and virtual reality, the Internet of Things, cloud computing, and autonomous vehicles.

Veterinarians and human medical doctors are collaborating on the trial in which the same immunotherapy is being used to treat people and dogs with glioma, the most aggressive form of brain cancer. Dogs and humans develop malignant brain tumors at about the same rate and with similar biology.

Dr. Renee Chambers, who holds a doctor of veterinary medicine degree from Auburn and a doctor of medicine degree from UAB, has received funding from the
National Institutes of Health for a multi-institutional consortium to evaluate immunotherapy for glioma tumors, the same type of brain cancer as the late Sen. John McCain had.